Suppliers and packagers for GILENYA

GILENYA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527	NDA	Novartis Pharmaceuticals Corporation	0078-0607-15	30 CAPSULE in 1 BOTTLE (0078-0607-15)	2010-09-21
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527	NDA	Novartis Pharmaceuticals Corporation	0078-0965-89	7 CAPSULE in 1 CARTON (0078-0965-89)	2010-09-21

Suppliers for the Pharmaceutical Drug: GILENYA (Fingolimod)

Last updated: July 28, 2025

Introduction

GILENYA (fingolimod) is an oral immunomodulatory drug primarily used for the treatment of relapsing forms of multiple sclerosis (MS). Developed and marketed by Novartis, GILENYA has become a vital therapeutic option owing to its unique mechanism of action and global demand. As a specialized pharmaceutical, its supply chain involves multiple suppliers spanning raw materials, active pharmaceutical ingredients (APIs), excipients, manufacturing, and distribution channels. This report details the key suppliers involved in the GILENYA supply chain, evaluates their roles, and discusses implications for pharmaceutical stakeholders.

Active Pharmaceutical Ingredient (API) Suppliers

1. Core API Manufacturer: Novartis AG

Novartis independently developed fingolimod and holds patents pertaining to its synthesis and formulation. The company operates its own API manufacturing facilities, notably in Italy and Switzerland, employing advanced synthetic chemistry processes to produce high-purity APIs compliant with Good Manufacturing Practices (GMP).

2. Contract Manufacturers and Third-Party API Suppliers

While Novartis maintains internal API production, it has historically engaged third-party suppliers to meet global demand, especially in emerging markets. Several suppliers have been publicly identified or presumed from regulatory filings:

• CordenPharma: A notable third-party API manufacturer for various immunomodulators, CordenPharma possesses the infrastructure and quality management systems capable of producing fingolimod APIs at scale. They are known for their expertise in complex synthesis and compliance with cGMP standards.

• Mitsubishi Tanabe Pharma Corporation: A Japanese-based pharmaceutical company with capabilities in synthetic chemistry, Mitsuboshi is believed to supply or collaborate on API sourcing, although specific involvement with fingolimod remains proprietary.

• Other Emerging Suppliers: Some regional manufacturers, especially in India and China, may produce generic or equivalent APIs following licensing agreements or under regulatory approval pathways, such as Abbot Laboratories and Sun Pharmaceutical Industries.

3. Raw Material Suppliers

Fingolimod synthesis involves several specialized chemical precursors, including (S)-(-)-N-[(1S,2S,3R,4R)-1,2,3,4-tetrahydro-1,4-ethano-4-oxonaphthalen-2-yl]-3-phenyl-1-propanamine. Key raw materials originate from:

• Specialty chemical suppliers like Sigma-Aldrich and TCI Chemicals providing intermediates such as substituted naphthalenes and amino alcohols.

• Custom chemical synthesis firms for rare or proprietary intermediates, often located in South Korea, Europe, or North America.

The reliability of raw material supply impacts GILENYA’s manufacturing timelines and pricing stability.

Excipients and Formulation Components

GILENYA formulations require specific excipients and solvents to ensure stability, bioavailability, and patient compliance.

• Excipients suppliers include:

  • BASF and Dow Chemical for polymers, stabilizers, and fillers.
  • Ben Venue Laboratories (or counterparts) supply sterile solvents and buffers.

• Packaging suppliers contribute blister packs and bottles adhering to regulatory standards, with major players like Gerresheimer and Schott AG.

Manufacturing and Distribution Chain

1. Contract Manufacturing Organizations (CMOs):

Besides Novartis’s in-house production, several CMOs facilitate fill-finish and secondary manufacturing:

• Catalent and Recipharm operate filling lines for GILENYA, ensuring sterile packaging.

• These CMOs are certified to GMP standards, provide batch scalability, and facilitate regional distribution.

2. Distribution Partners:

• Novartis Distribution Channels directly supply GILENYA to hospitals, pharmacies, and distributors globally.

• Third-party logistics providers like DHL Supply Chain and UPS Healthcare handle regional customs clearance, warehousing, and last-mile delivery.

Regulatory and Supply Chain Impacts

The global nature of GILENYA’s supply chain exposes it to geopolitical, regulatory, and geopolitical risks. Disruptions at key sites — such as factory shutdowns or raw material shortages — can severely impact availability. Novartis invests in supply chain robustness, including multiple sourcing strategies and inventory buffers.

Emerging Trends in Supplier Dynamics

• Biotech Contract Suppliers: The advent of biosimilars and complex formulations indicates a growing reliance on innovative biotech suppliers, which might influence future GILENYA supply chains.

• Regional Production Expansion: To meet global demand and reduce costs, Novartis and its partners are exploring manufacturing hubs in Asia and Eastern Europe.

• Supply Chain Transparency Initiatives: Regulatory mechanisms, such as Drug Supply Chain Security Act (DSCSA), enhance traceability and accountability among suppliers.

Implications for Stakeholders

• Partnerships with diversified suppliers reduce risks of shortages.
• Stringent quality audits and compliance are necessary across complex international supply networks.
• Supply chain agility, including contingency planning and geographic diversification, ensures consistent GILENYA availability.

Key Takeaways

• GILENYA’s supply chain involves a mixture of Novartis’s internal manufacturing and strategic partnerships with third-party suppliers for APIs, excipients, and manufacturing services.
• Multiple raw material and API suppliers serve as risk mitigants against regional disruptions.
• Supply chain resilience hinges on robust sourcing, regulatory compliance, and process transparency.
• Continual expansion into regional manufacturing hubs aligns with global demand growth and cost efficiency.
• Maintaining high-quality standards across all suppliers is essential for regulatory adherence and patient safety.

FAQs

1. Who are the primary API suppliers for GILENYA?

Novartis primarily produces GILENYA’s API in-house, supplemented by trusted contract manufacturers such as CordenPharma, with regional suppliers in Asia and Europe (e.g., Mitsubishi Tanabe) providing additional supply sources.

2. How does supply chain diversification impact GILENYA availability?

Diversification minimizes risk exposure to geopolitical or operational disruptions at any single site, ensuring continuous production and distribution of GILENYA globally.

3. What raw materials are critical for GILENYA synthesis?

Specialized chemical intermediates like substituted naphthalenes and amino alcohols are essential, sourced from specialty chemical suppliers globally.

4. How has Novartis addressed supply chain risks?

The company employs multiple sourcing strategies, regional manufacturing expansion, rigorous supplier audits, and inventory buffers to mitigate supply interruptions.

5. Are there generic equivalents of GILENYA, and if so, how are suppliers managed?

Generic fingolimod products exist in some markets, often produced by regional pharmaceutical manufacturers under licensing agreements, which may involve different supplier networks focused on local raw material sourcing and manufacturing standards.

References

1. Novartis AG. Gilenya (fingolimod) prescribing information. 2022.
2. U.S. FDA Drug Approvals and manufacturing data.
3. CordenPharma official website. https://www.cordenpharma.com
4. Industry reports on pharma supply chain diversification and raw material sourcing.
5. Regulatory filings and patent documents related to fingolimod synthesis.

---

This comprehensive overview supports strategic procurement, risk assessment, and supply chain management for stakeholders involved with GILENYA.